DK1268799T3 - Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitet - Google Patents
Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitetInfo
- Publication number
- DK1268799T3 DK1268799T3 DK01922997T DK01922997T DK1268799T3 DK 1268799 T3 DK1268799 T3 DK 1268799T3 DK 01922997 T DK01922997 T DK 01922997T DK 01922997 T DK01922997 T DK 01922997T DK 1268799 T3 DK1268799 T3 DK 1268799T3
- Authority
- DK
- Denmark
- Prior art keywords
- cadherin
- human
- antibody
- adverse effects
- vascular permeability
- Prior art date
Links
- 102000008790 VE-cadherin Human genes 0.000 title abstract 2
- 108010018828 cadherin 5 Proteins 0.000 title abstract 2
- 230000002411 adverse Effects 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000008728 vascular permeability Effects 0.000 title 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 abstract 3
- 241001529936 Murinae Species 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000011161 development Methods 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 238000012910 preclinical development Methods 0.000 abstract 1
- 238000001262 western blot Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54096700A | 2000-03-31 | 2000-03-31 | |
| PCT/US2001/010505 WO2001075109A2 (en) | 2000-03-31 | 2001-03-30 | Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1268799T3 true DK1268799T3 (da) | 2009-07-06 |
Family
ID=24157649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01922997T DK1268799T3 (da) | 2000-03-31 | 2001-03-30 | Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitet |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7371574B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1268799B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003529370A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE425255T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2001249737A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2404576A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1109097T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60137915D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1268799T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2323938T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1268799E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001075109A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
| EP1560850A2 (en) * | 2002-11-14 | 2005-08-10 | Adherex Technologies, Inc. | Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| JP2004175689A (ja) * | 2002-11-25 | 2004-06-24 | Kureha Chem Ind Co Ltd | 癌転移抑制剤 |
| US20040167076A1 (en) * | 2003-02-14 | 2004-08-26 | Stamer W. Daniel | Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells |
| GB0602063D0 (en) | 2006-02-02 | 2006-03-15 | Univ Manchester | Cell Culture |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| WO2011071541A2 (en) * | 2009-12-11 | 2011-06-16 | The Scripps Research Institute | Cadherin modulatory agents |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5036003A (en) * | 1987-08-21 | 1991-07-30 | Monsanto Company | Antibodies to VPF |
| WO1993008210A1 (en) * | 1991-10-18 | 1993-04-29 | Beth Israel Hospital Association | Vascular permeability factor targeted compounds |
| US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| WO1993017715A1 (en) * | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| JPH07500019A (ja) * | 1992-04-17 | 1995-01-05 | ドーニー アイ インスティテュート | カドヘリン物質および方法 |
| US5646250A (en) * | 1992-04-17 | 1997-07-08 | Doheny Eye Institute | Cadherin polypeptides |
| US5597725A (en) * | 1992-04-17 | 1997-01-28 | Doheny Eye Institute | Cadherin-specific antibodies and hybridoma cell lines |
| US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US5730977A (en) * | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| US20050222037A1 (en) * | 1998-05-05 | 2005-10-06 | Adherex Technologies, Inc. | Compounds and methods for modulating VE-cadherin-mediated function |
| CA2327530A1 (en) * | 1998-05-05 | 1999-11-11 | Adherex Technologies, Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| US20030206902A1 (en) * | 2001-03-05 | 2003-11-06 | Fang Liao | Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis |
-
2001
- 2001-03-30 DK DK01922997T patent/DK1268799T3/da active
- 2001-03-30 JP JP2001572983A patent/JP2003529370A/ja active Pending
- 2001-03-30 WO PCT/US2001/010505 patent/WO2001075109A2/en not_active Ceased
- 2001-03-30 AU AU2001249737A patent/AU2001249737A1/en not_active Abandoned
- 2001-03-30 PT PT01922997T patent/PT1268799E/pt unknown
- 2001-03-30 EP EP01922997A patent/EP1268799B1/en not_active Expired - Lifetime
- 2001-03-30 ES ES01922997T patent/ES2323938T3/es not_active Expired - Lifetime
- 2001-03-30 CA CA002404576A patent/CA2404576A1/en not_active Abandoned
- 2001-03-30 DE DE60137915T patent/DE60137915D1/de not_active Expired - Lifetime
- 2001-03-30 AT AT01922997T patent/ATE425255T1/de active
-
2002
- 2002-01-02 US US10/040,128 patent/US7371574B2/en not_active Expired - Fee Related
-
2008
- 2008-03-26 US US12/056,173 patent/US20090060909A1/en not_active Abandoned
- 2008-03-26 US US12/056,146 patent/US20080317750A1/en not_active Abandoned
- 2008-03-26 US US12/056,116 patent/US20080311121A1/en not_active Abandoned
-
2009
- 2009-05-25 CY CY20091100557T patent/CY1109097T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080311121A1 (en) | 2008-12-18 |
| US20090060909A1 (en) | 2009-03-05 |
| DE60137915D1 (de) | 2009-04-23 |
| JP2003529370A (ja) | 2003-10-07 |
| EP1268799A2 (en) | 2003-01-02 |
| WO2001075109A2 (en) | 2001-10-11 |
| ES2323938T3 (es) | 2009-07-28 |
| CA2404576A1 (en) | 2001-10-11 |
| US20020160003A1 (en) | 2002-10-31 |
| ATE425255T1 (de) | 2009-03-15 |
| US20080317750A1 (en) | 2008-12-25 |
| CY1109097T1 (el) | 2014-07-02 |
| AU2001249737A1 (en) | 2001-10-15 |
| EP1268799B1 (en) | 2009-03-11 |
| US7371574B2 (en) | 2008-05-13 |
| PT1268799E (pt) | 2009-05-11 |
| WO2001075109A3 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109097T1 (el) | Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας | |
| DE69735294D1 (de) | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen | |
| DE69230545D1 (de) | Antikörperderivate | |
| PH12022551650A1 (en) | Anti-trem2 antibodies and methods of use thereof | |
| DK130791D0 (da) | Monoklonale antistoffer, isaer for hb alc. | |
| DE60334364D1 (de) | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern | |
| PH12021552002A1 (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL138497A0 (en) | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen | |
| ES2082775T3 (es) | Anticuerpos de proteinas latentes de papilomavirus humano, sistemas de diagnostico y procedimientos. | |
| ATE158415T1 (de) | Kationisierte antikörper gegen intrazelluläre eiweisse | |
| DK0552296T3 (da) | Monoklonale antistoffer fra mus | |
| DE69932812D1 (de) | Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe | |
| DK0946873T3 (da) | Fremgangsmåde til diagnose af allergisk bronkopulmonal aspergillose | |
| ATE429449T1 (de) | Anti-fas-ligand antikörper und testmethode unter verwendung derselben | |
| SE8300320D0 (sv) | Monoclonal antibody formulation for diagnostic use | |
| KR900018365A (ko) | 모노클로날 항체 및 이의 용도 | |
| ATE230418T1 (de) | Monoklonaler antikörper gegen das humane mx- protein mxa | |
| NO930705L (no) | Fremgangsmaate for bestemmelse av en vannbehandlingspolymer i en vandig proeve | |
| DE68921360D1 (de) | Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus. | |
| MX2007006895A (es) | Deteccion de un anticuerpo terapeutico en animal de experimentacion. | |
| DE69529744D1 (de) | Monoklonale antikörper spezifisch gegen vaskuläres endothelzellartigen endoglyx-1, das antigen selbst und seine verwendungen | |
| CN103163300B (zh) | 人n-乙酰氨基半乳糖转移酶2双抗体夹心elisa试剂盒 | |
| IT8021411A0 (it) | Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione. | |
| DE3785175D1 (de) | A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung. | |
| DK0537168T3 (da) | Antigenet CTAA 28A32, som genkendes af MCA 28A32 |